Efficacy of immune checkpoint inhibitors plus platinum-based chemotherapy as 1st line treatment for patients with non-small cell lung cancer harboring HER2 mutations: Results from LC-SCRUM-Asia.

doi:10.1016/j.lungcan.2024.107992

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Efficacy of immune checkpoint inhibitors plus platinum-based chemotherapy as 1st line treatment for patients with non-small cell lung cancer harboring HER2 mutations: Results from LC-SCRUM-Asia.

Lung cancer (Amsterdam, Netherlands) - 1 Nov 2024

Kato Yuki, Udagawa Hibiki, Matsumoto Shingo, Izumi Hiroki, Ohe Yuichiro, Kato Terufumi, Nishino Kazumi, Miyamoto Shingo, Kawana Sachiko, Chikamori Kenichi, Shingyoji Masato, Sato Yuki, Takada Yuji, Toyozawa Ryo, Azuma Koichi, Tanaka Yu, Sakai Tetsuya, Shibata Yuji, Sugiyama Eri, Nosaki Kaname, Zenke Yoshitaka, Umemura Shigeki, Yoh Kiyotaka, Seike Masahiro, Goto Koichi

Abstract excerpt

INTRODUCTION: HER2 mutations are reported to occur in 2%-5% of all cases of non-small cell lung cancer (NSCLC). The clinical outcomes in patients with HER2-mutant NSCLC treated with immune checkpoint inhibitors (ICIs) plus platinum-based chemotherapy as 1st line treatment still remain unclear. METHODS: Using the large-scale clinico-genomic database of LC-SCRUM-Asia, the clinico-genomic characteristics and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Carcinoma, Non-Small-Cell Lung

Share to Erb-b2 Receptor Tyrosine Kinases

Share to Immune Checkpoint Inhibitors

Share to Lung Neoplasms

Share to Platinum

Share to Prognosis

Source

Open in PubMed

Identifiers

PMID: 39423763
DOI: 10.1016/j.lungcan.2024.107992

Genes

ALK
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy of immune checkpoint inhibitors plus platinum-based chemotherapy as 1st line treatment for patients with non-small cell lung cancer harboring HER2 mutations: Results from LC-SCRUM-Asia.PMID 39423763Read ↗

Real-world therapeutic strategies and survival outcomes in advanced HER2 -mutant non-small cell lung cancer.Semantic proximity Read ↗

Genomic and immune characteristics of HER2-mutated non-small-cell lung cancer and response to immune checkpoint inhibitor-based therapy.Semantic proximity Read ↗

Real-World Prevalence, Treatment Patterns, and Outcomes for Patients With HER2 (ERBB2)-Mutant Metastatic Non-Small Cell Lung Cancer, From a US-Based Clinico-Genomic Database.Semantic proximity Read ↗

Efficacy of chemotherapy plus immune checkpoint inhibitors in patients with non-small cell lung cancer who have rare oncogenic driver mutations: a retrospective analysis.Semantic proximity Read ↗

Real-World Patient Characteristics, Mutational Landscape, and Outcomes in Advanced/Metastatic HER2-Mutant Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Efficacy of first-line immune checkpoint inhibitors in patients with advanced NSCLC with KRAS, MET, FGFR, RET, BRAF, and HER2 alterations.Semantic proximity Read ↗

Subtypes of EGFR- and HER2-Mutant Metastatic NSCLC Influence Response to Immune Checkpoint Inhibitors.Semantic proximity Read ↗

Clinical outcomes for immune checkpoint inhibitors plus chemotherapy in non-small-cell lung cancer patients with uncommon driver gene alterations.Semantic proximity Read ↗

Treatment Outcome and Clinical Characteristics of HER2 Mutated Advanced Non-Small Cell Lung Cancer Patients in ChinaSemantic proximity Read ↗

EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study.Semantic proximity Read ↗

Lung Cancer That Harbors an <i>HER2</i> Mutation: Epidemiologic Characteristics and Therapeutic PerspectivesSemantic proximity Read ↗

Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.